Growing Insulin and GLP-1 Drugs in Plants and Algae to Make Them Affordable
Plant- and microalgae-based biotechnology could dramatically reduce the cost of producing insulin and GLP-1 drugs while enabling oral delivery.
Quick Facts
What This Study Found
Plant- and microalgae-based biotechnological platforms offer affordable production and non-invasive (oral) delivery strategies for antidiabetic peptides including insulin and GLP-1 RAs.
Key Numbers
How They Did This
Review of biotechnological strategies for producing antidiabetic peptides in plant and microalgae systems, evaluating cost reduction and oral delivery potential.
Why This Research Matters
Diabetes drug costs are a global crisis. Making insulin and GLP-1 drugs in plants could reduce costs by orders of magnitude and eliminate injection barriers.
The Bigger Picture
Plant molecular farming could disrupt pharmaceutical manufacturing for peptide drugs, making treatments accessible in low- and middle-income countries where diabetes burden is growing fastest.
What This Study Doesn't Tell Us
Review of emerging technology — most plant-produced peptides are still in development. Regulatory hurdles, dosing consistency, and stability remain significant challenges.
Questions This Raises
- ?How soon could plant-produced insulin be commercially available?
- ?Can plant-produced GLP-1 drugs achieve the same efficacy as synthetic versions?
Trust & Context
- Key Stat:
- Affordable + oral delivery Plant/algae production could cut costs and enable oral antidiabetic peptide delivery
- Evidence Grade:
- Review of biotechnology platforms — summarizes potential but most systems remain in development.
- Study Age:
- Published in 2026; covers the latest plant molecular farming advances.
- Original Title:
- Plant- and Microalgae-Based Biotechnological Strategies for Affordable and Non-Invasive Delivery of Antidiabetic Peptides.
- Published In:
- Pharmaceutics, 18(2) (2026)
- Authors:
- Boscart, Thibault, Barras, Alexandre, Plaisance, Valérie, Pawlowski, Valérie, Giovanelli, Emerson, Bardor, Muriel, D'Hulst, Christophe, Abderrahmani, Amar
- Database ID:
- RPEP-14897
Evidence Hierarchy
Frequently Asked Questions
Can plants produce insulin?
Yes — plants and microalgae can be genetically engineered to produce human insulin and GLP-1 drugs. This could dramatically reduce manufacturing costs and potentially enable oral delivery.
Would plant-produced insulin be safe?
Plant-produced peptides must meet the same safety and purity standards as conventionally manufactured drugs. Regulatory frameworks are being developed, and early results show promising quality.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14897APA
Boscart, Thibault; Barras, Alexandre; Plaisance, Valérie; Pawlowski, Valérie; Giovanelli, Emerson; Bardor, Muriel; D'Hulst, Christophe; Abderrahmani, Amar. (2026). Plant- and Microalgae-Based Biotechnological Strategies for Affordable and Non-Invasive Delivery of Antidiabetic Peptides.. Pharmaceutics, 18(2). https://doi.org/10.3390/pharmaceutics18020223
MLA
Boscart, Thibault, et al. "Plant- and Microalgae-Based Biotechnological Strategies for Affordable and Non-Invasive Delivery of Antidiabetic Peptides.." Pharmaceutics, 2026. https://doi.org/10.3390/pharmaceutics18020223
RethinkPeptides
RethinkPeptides Research Database. "Plant- and Microalgae-Based Biotechnological Strategies for ..." RPEP-14897. Retrieved from https://rethinkpeptides.com/research/boscart-2026-plant-and-microalgaebased-biotechnological
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.